Drug chief uncomfortable over fund

SMR   Window

A cash pot used to pay for life-extending drugs should not be limited to patients who have cancer, the head of the National Institute for Health and Clinical Excellence has suggested.

You need to be signed in to read more


Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All of HSJ.co.uk and our HSJ mobile app
  • News and insight on all areas of public funded healthcare
  • Expert commentary, insight and analysis from industry leaders
  • 9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

Sign into your account here